The protective effect of erdosteine against ototoxicity induced by cisplatin in rats.
The elimination of cisplatin ototoxicity is an ongoing concern. This experimental study was undertaken to investigate the effect of oral erdosteine in ameliorating cisplatin-induced ototoxicity. Twenty-eight adult female Wistar albino rats were randomly divided into four equal groups. Group A received an oral carrier vehicle of the drug erdosteine with 0.2 ml of 0.9% saline. Group B was administered only erdosteine (per oral 10 mg/kg twice a day) for 6 days. Group C was injected with cisplatin intraperitoneally (i.p.) on day 0 (16 mg/kg body weight), once only. Group D was given erdosteine (per oral 10 mg/kg/day) 1 day before and for 5 days consecutively after cisplatin injection (16 mg/kg, i.p.). Distortion product otoacoustic emissions (DPOAEs) were elicited in different frequency regions, ranging from 1,001 to 6,299 Hz as DPgram and input/output (I/O) functions from the control and experimental animals. All experimental animals were killed under general anesthesia on day 5, following the last otoacoustic emission measurements. Prior to death, blood samples were drawn for measurement of superoxide dismutase, xanthine oxidase (XO), malondialdehyde and nitric oxide. Initial DPgram and I/O function baseline measurements were similar in all groups prior to any drug administration ( P>0.05). On day 5, intra-subject measurement parameters of DPgrams and I/O functions in the cisplatin group showed significant deterioration ( P <0.05). The other groups revealed no differences between their pre- and post-test drug administration DPgrams and I/O functions at any test frequency ( P>0.05). Comparison of the amplitudes of DPgrams and I/O functions between the cisplatin and control groups showed significant changes ( P <0.05). Biochemical studies noted an increased XO activity following cisplatin administration ( P <0.007). The other biochemical results did not show significant differences between the study and control groups. This study demonstrates that, in rats, erdosteine is protective for cochlear function against the disruptive effects of cisplatin as measured by DPOAEs.
Kalcioglu
M Tayyar
MT
Department of Otorhinolaryngology, Inonu University Medical School, Turgut Ozal Medical Center, 44069, Malatya, Turkey. mtkalcioglu@hotmail.com
Kizilay
Ahmet
A
Gulec
Mukaddes
M
Karatas
Erkan
E
Iraz
Mustafa
M
Akyol
Omer
O
Egri
Mucahit
M
Ozturan
Orhan
O
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000975:Antioxidants / Q000008:administration & dosage / Q000627:therapeutic use*; D002945:Cisplatin / Q000009:adverse effects*; D005260:Female; D034381:Hearing Loss / Q000517:prevention & control*; D008315:Malondialdehyde / Q000097:blood; D009569:Nitric Oxide / Q000378:metabolism; D017084:Otoacoustic Emissions, Spontaneous / Q000502:physiology; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D017382:Reactive Oxygen Species / Q000378:metabolism; D013482:Superoxide Dismutase / Q000378:metabolism; D013864:Thioglycolates / Q000008:administration & dosage / Q000627:therapeutic use*; D013876:Thiophenes / Q000008:administration & dosage / Q000627:therapeutic use*; D014969:Xanthine Oxidase / Q000097:blood
D000970:Antineoplastic Agents; D000975:Antioxidants; D017382:Reactive Oxygen Species; D013864:Thioglycolates; D013876:Thiophenes; D009569:Nitric Oxide; D008315:Malondialdehyde; C048498:erdosteine; D013482:Superoxide Dismutase; D014969:Xanthine Oxidase; D002945:Cisplatin
Pharmacol Toxicol. 1995 Jun;76(6):386-94
7479581
Am J Otol. 1997 Sep;18(5):559-71
9303151
Hear Res. 1996 Dec 1;102(1-2):90-8
8951454
Otolaryngol Head Neck Surg. 2000 Jun;122(6):828-33
10828794
Clin Chem. 1988 Mar;34(3):497-500
3349599
Otol Neurotol. 2004 Jan;25(1):33-40
14724489
Hear Res. 1996 Sep 1;98(1-2):116-24
8880186
Clin Chem. 1990 Aug;36(8 Pt 1):1440-3
2387039
Int J Dev Neurosci. 2000 Apr-Jun;18(2-3):259-70
10715580
Arch Otolaryngol Head Neck Surg. 1994 May;120(5):541-6
8172706
Curr Opin Otolaryngol Head Neck Surg. 2003 Oct;11(5):328-33
14502062
Inflamm Res. 1999 Apr;48(4):205-9
10344471
J Pineal Res. 2000 Mar;28(2):73-80
10709968
Arzneimittelforschung. 2000 Aug;50(8):739-46
10994158
Br J Cancer. 2003 Apr 22;88(8):1199-206
12698184
Urol Res. 2001 Jun;29(3):190-3
11482445
Urol Res. 2000 Dec;28(6):360-3
11221913
Int J Clin Pharmacol Ther Toxicol. 1989 May;27(5):238-41
2786856
Int J Clin Pharmacol Ther Toxicol. 1989 May;27(5):235-7
2786855
Drugs. 1996 Dec;52(6):875-81; discussion 882
8957158
J Am Acad Audiol. 2003 Apr;14(3):144-56
12859139
Respiration. 1989;55(2):113-8
2788908
Pharmacol Res. 2003 Apr;47(4):317-22
12644389
Clin Chim Acta. 2003 May;331(1-2):111-7
12691871
Arch Otolaryngol Head Neck Surg. 1993 Jun;119(6):661-6
8499098
Farmaco. 1994 Nov;40(11):703-8
7832972
Eur J Cancer. 2004 Jul;40(11):1713-23
15251161
Methods Enzymol. 1990;186:407-21
2233308
Auris Nasus Larynx. 1996;23:147-51
8809338
Pharmacol Res. 2003 Feb;47(2):149-56
12543063
FEBS Lett. 1975 Nov 15;59(2):245-9
179860